Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Autor:	Löfgren, L., Wallberg, B., Wilking, N., Fornander, T., Rutqvist, L., Carlström, K., Schoultz, B., Schoultz, E., Löfgren, L, Rutqvist, L E, Carlström, K, von Schoultz, B, von Schoultz, E
Předmět:	GLYCOPROTEIN analysis ANTINEOPLASTIC agents BREAST tumors CLINICAL trials COMBINED modality therapy COMPARATIVE studies LONGITUDINAL method RESEARCH methodology MEDICAL cooperation SYNTHETIC progestagens RESEARCH SOMATOMEDIN TESTOSTERONE TAMOXIFEN EVALUATION research RANDOMIZED controlled trials POSTMENOPAUSE THERAPEUTICS
Zdroj:	Medical Oncology; Dec2004, Vol. 21 Issue 4, p309-318, 10p
Abstrakt:	Aim: To compare the effects of tamoxifen and megestrol acetate on liver proteins, androgens, and glucocorticoids during adjuvant treatment for postmenopausal breast cancer.Methods: A subgroup of women within a large prospective multicenter trial were followed with blood sampling every 3 mo during 2 yr. Women were randomized to receive either continuous tamoxifen 40 mg/d or repeated sequential treatment with tamoxifen and megestrol acetate (MA) 160 mg/d.Results: We found profound and distinct differences between the two regimens. Tamoxifen increased steroid-binding proteins (SHBG and CBG) and suppressed circulating androgens and IGF-I. In contrast, the metabolic effects of tamoxifen were clearly antagonized by MA. There was a rise in IGF-I and marked suppression of steroid-binding proteins. Levels of free testosterone were reduced by 70%. MA also caused apparent adrenal suppression.Conclusion: The different effects on anabolic/catabolic balance and adrenal function may relate to certain clinical effects during treatment. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink